(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 12.6MM | - |
Gross Profit | 7.8MM | - |
Cost Of Revenue | 4.7MM | - |
Operating Income | 5.6MM | -394% |
Operating Expenses | 2.3MM | -42% |
Net Income | 4.2MM | -390% |
R&D | 675K | -38% |
G&A | 952K | -37% |
Marketing | 624K | -52% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Management will discuss its new “Fair Deal Agreement” for its SRT-100 Vision™ IG-SRT in one-on-one meetings in Dana Point, California on March 18th and 19th BOCA RATON, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces management will participate in one-on-one or small group meetings with
New shared service contract expands the unmatched clinical results achieved with IG-SRT to a broader base of prospective customers Active traffic at the Company’s booth generated a record-high number of sales leads and affirms very strong interest in a better economic choice BOCA RATON, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncol
While people tend to avoid price hikes, certain stocks up 100% this year just might provide an exception to the rule. Basically, not even two months have passed by. If these securities are already up by a blistering magnitude, there could be more rewards in store. Put another way, robust strength may beget even more strength. Broadly speaking the fear of missing out (FOMO) represents a powerful catalyst, especially in the post-pandemic cycle. For example, we’ve already seen how struggling gaming
Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Shareholders will be ecstatic, with their stake up 23% over the past week following Sensus Healthcare, Inc. 's...
Sensus Healthcare, Inc. (NASDAQ:SRTS) Q4 2023 Earnings Call Transcript February 8, 2024 Sensus Healthcare, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome to the Sensus Healthcare Fourth Quarter and Full Year 2023 Financial Results Conference […]
Q4 2023 Sensus Healthcare Inc Earnings Call
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 116.67% and 3.89%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Fourth quarter revenues of $12.6 million up three-fold sequentially, reflect ongoing customer adjustment to macroeconomic conditionsIntroduces recurring revenue model for the SRT-100 Vision™ (IG-SRT) to address dermatologist demand Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments
BOCA RATON, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that the U.S. Patent and Trademark Office (USPTO) has issued Patent No. 11,894,123 B2, titled “Radiotherapy Mobile and Wireless Device Workflow Management System.” This new patent covers systems and methods for treating a patien